Loading peptide directory…
Side-by-side
Pick up to 3 peptides and see their key facts side by side. Useful for narrowing a search before deciding which page to read in full.
1 of 3 selected.
| Field | Last updated |
|---|---|
| Aliases | IBI362, LY3305677, Oxyntomodulin analogue, Innovent dual GLP-1/glucagon agonist |
| Category | Metabolic |
| Formula | — |
| Molecular weight | 4500 Da |
| Half-life | ~7 days |
| Mechanism (summary) | Mazdutide (IBI362, LY3305677) is a once-weekly synthetic oxyntomodulin analogue with a fatty-acyl moiety for extended exposure. It is a dual GLP-1R / GCGR agonist. Innovent has reported NMPA approval in China for chronic weight management and later for glycemic control in adults with type 2 diabetes; outside China it remains investigational. |
| Dosing notes | Approved-in-China use is once-weekly subcutaneous. Main approved or near-approved weekly maintenance doses are 4 mg and 6 mg, with earlier obesity work going up to 6 mg via dose escalation and later obesity studies examining 9 mg and 10 mg. Detailed English-language approved titration instructions were not recoverable from the reviewed sources. |
| Storage | Unspecified in the reviewed official English-language sources. An accessible English package insert with authoritative storage conditions was not located; defer to the brand-specific Chinese label for current storage guidance. |
|---|
| Read more | Full reference → |
|---|